Fate Therapeutics & Whitehead Institute v. Lonza: Federal Circuit Appeal Voluntarily Dismissed
Fate Therapeutics and the Whitehead Institute brought a seven-patent infringement appeal to the Federal Circuit targeting Lonza’s two-step iPSC reprogramming and direct manufacturing processes. The proceeding was voluntarily dismissed after 398 days — leaving the merits unresolved and the public record silent on terms.
Seven iPSC Patents, One Voluntary Exit at the Federal Circuit
Fate Therapeutics, Inc. and the Whitehead Institute for Biomedical Research jointly filed this Federal Circuit appeal on October 5, 2023, asserting infringement of seven US patents covering induced pluripotent stem cell (iPSC) reprogramming technology. The patents in suit — spanning application families dating from 2010 to 2018 — cover core methods for generating and manufacturing iPSCs, a foundational technology in cell therapy. The accused products were Lonza’s two-step reprogramming process and its iPSC direct manufacturing processes.
The proceeding was terminated on November 6, 2024, when the plaintiffs voluntarily dismissed the appeal. The Federal Circuit’s docket records the outcome as ‘Voluntary dismissal,’ but does not publicly specify whether the dismissal was with or without prejudice. This distinction is commercially significant: a dismissal with prejudice would bar refiling, while a dismissal without prejudice could preserve the option to re-assert these patents in future proceedings.
At 398 days, the case closed within a typical Federal Circuit timeline, suggesting the parties may have reached an off-record resolution before full briefing or oral argument concluded. What drove the voluntary exit — whether settlement, licensing, or strategic withdrawal — cannot be confirmed from the public record. Seven patents across multiple application families remaining unlitigated to a merits decision leaves meaningful uncertainty for competitors operating in the iPSC manufacturing space.
Filing to Voluntary dismissal in 398 days
398 days — Federal Circuit appeals typically resolve in 12–18 months
Voluntarily dismissed: what the silent record means for both parties
Voluntary dismissal ends the appeal without a merits ruling
A voluntary dismissal at the Federal Circuit means the appealing parties withdrew their proceeding before the court issued any substantive ruling. No finding of infringement, validity, or claim construction was made. The Federal Circuit record shows only that the proceeding was dismissed — it does not specify whether the dismissal was with or without prejudice, leaving the legal finality of this outcome ambiguous from the public docket alone.
No merits adjudicationWith or without prejudice? The public record is silent
This distinction matters enormously. A dismissal with prejudice operates as a final judgment — the plaintiffs cannot re-assert the same claims against the same accused products. A dismissal without prejudice preserves the right to refile. The public docket for Case No. 24-1021 does not resolve this question. Parties with competitive exposure to these seven iPSC patents should not assume either outcome without reviewing underlying court filings or any associated district court orders.
Prejudice status undisclosedSeven patents exit the Federal Circuit unvalidated — and unenforced
Fate Therapeutics and Whitehead Institute withdrew without securing any affirmance of infringement or validity across seven patents. The patents themselves remain in force as issued, but the appeal produced no judicial endorsement of their scope or strength. If the dismissal was without prejudice, the patent holders retain enforcement options; if with prejudice on the asserted claims, their appellate route against Lonza on this record is closed.
Patents in force, merits unresolvediPSC manufacturers face unresolved patent risk across a 7-patent family
Lonza and other iPSC contract manufacturers operating two-step or direct reprogramming workflows cannot treat this dismissal as a clean bill of health. No court ruled these patents invalid or not infringed. The technology covered — iPSC generation and manufacturing methods — is commercially central to the cell therapy supply chain. Competitors and licensees should treat the underlying patent family as active risk and conduct fresh FTO analysis against the seven asserted patents.
Ongoing FTO risk for iPSC sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Fate Therapeutics, Inc. | Company | Cell therapy and iPSC research organizations — holders of US10457917B2 and 6 related patentsSearch in Eureka ↗ |
| Co-Plaintiff | Whitehead Institute For Biomedical Research | Individual | Search in Eureka ↗ |
| Defendant | Defendant | Individual | Lonza Group — contract developer and manufacturer of iPSC-based cell therapy productsSearch in Eureka ↗ |
| Plaintiff counsel | Andrew S. Ong | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher J.C. Herbert | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan D. Ball Ph.D. | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin P. Martin | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Rose Cordero Prey | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing Fate Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Greenberg Traurig LLP | Law Firm | Representing Fate Therapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge MarilynL. Huff | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition — ‘The proceeding is DISMISSED’ on a voluntary basis — reflects a party-initiated termination rather than any judicial assessment of the merits. At the appellate level, a voluntary dismissal leaves the lower court record (and any underlying district court rulings) undisturbed, but produces no precedential or persuasive authority on the patents’ validity or infringement scope. Because the public record does not specify whether dismissal was with or without prejudice, the preclusive effect on future enforcement remains legally ambiguous.
US10457917B2 — iPSC generation and reprogramming method patents
The seven patents in suit span a foundational iPSC technology portfolio originating from the Whitehead Institute, with application filings ranging from 2010 (US12/703015, US12/703061) through 2018 (US16/030815). The patents collectively cover methods for reprogramming somatic cells into induced pluripotent stem cells — a Nobel Prize-recognised advance that underpins modern cell therapy manufacturing. Claims across the family address factor combinations, process conditions, and manufacturing workflows central to both research-grade and clinical-grade iPSC production.
Strategically, this portfolio sits at the upstream chokepoint of the cell therapy supply chain. Any CDMO or developer using two-step or direct iPSC reprogramming — the dominant commercial approaches — operates within the potential claim scope of this family. The Whitehead Institute’s co-ownership signals academic-origin IP with broad foundational claims, a profile that historically commands strong licensing leverage. With no invalidity ruling on record, the commercial risk for unlicensed iPSC manufacturers remains unresolved.
Should your iPSC manufacturing process be assessed against this 7-patent family?
Any organisation developing, manufacturing, or contracting iPSC-based cell therapies — including CDMOs, autologous and allogeneic cell therapy developers, and research tool providers — should treat this patent family as a priority FTO target. The asserted patents cover process-level claims across reprogramming factor use, two-step workflows, and direct manufacturing. A process change or platform selection made without FTO analysis against all seven patents creates unquantified litigation exposure.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their specific iPSC manufacturing workflow against each of the seven patents’ independent and dependent claims simultaneously. The tool surfaces claim-by-claim overlap analysis, identifies design-around opportunities, and flags any pending continuation applications in the same family — giving your team a defensible clearance record before entering clinical manufacturing or CDMO partnership agreements.
Run a freedom-to-operate analysis on US10457917B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals involving iPSC and cell therapy patents
Cases involving foundational iPSC and cell therapy process patents at the Federal Circuit, including voluntary dismissals and infringement appeals in the biotechnology manufacturing sector.
What this case signals for the iPSC and cell therapy IP landscape
A seven-patent Federal Circuit appeal ending in voluntary dismissal rarely signals a clear winner — and in the iPSC manufacturing sector, the ambiguity compounds competitive risk.
Voluntary dismissal is not a validity ruling — treat the patents as live
No court assessed infringement or validity of the seven asserted patents. Companies operating iPSC reprogramming or direct manufacturing workflows — including CDMOs and cell therapy developers — should not interpret this dismissal as clearing the IP landscape. The Whitehead/Fate patent family remains enforceable as issued.
Seven-patent families require portfolio-level FTO, not claim-by-claim review
With seven patents across multiple application families spanning 2010–2018 filings, the claim landscape is layered. Any FTO analysis for iPSC manufacturing processes must map each patent’s independent claims against current workflows. A gap in one patent’s coverage does not resolve risk across the family.
Fate v Defendant — key questions answered
Fate Therapeutics and the Whitehead Institute voluntarily dismissed their Federal Circuit appeal (Case No. 24-1021) on November 6, 2024, after 398 days. The appeal involved seven US patents covering iPSC reprogramming methods asserted against Lonza’s two-step and direct manufacturing processes. No merits ruling was issued.
The public Federal Circuit docket for Case No. 24-1021 records a ‘Voluntary dismissal’ but does not specify whether it was with or without prejudice. This distinction — which determines whether the patents can be re-asserted against Lonza on the same claims — is not resolvable from public records alone.
Seven US patents were asserted: US10457917B2, US8071369B2, US9169490B2, US8951797B2, US8940536B2, US10017744B2, and US8932856B2. These patents cover methods for generating and manufacturing induced pluripotent stem cells, with application filings spanning 2010 to 2018.
No. A voluntary dismissal produces no judicial finding on infringement or validity. The Federal Circuit did not assess whether Lonza’s two-step reprogramming or direct manufacturing processes infringe any of the seven asserted patents. The patents remain in force as issued and the infringement question is unresolved.
Because no court invalidated any of the seven asserted patents or found non-infringement, iPSC manufacturers and CDMOs operating two-step or direct reprogramming workflows retain exposure. Companies should conduct a fresh freedom-to-operate analysis against all seven patents, including review of any continuation applications, before scaling clinical manufacturing or entering new CDMO agreements.
PatSnap Eureka searches patents and litigation data to answer instantly.